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Abstract
Background: Previous influenza surveillance at paediatric intensive care units (PICUs) in Germany indicated
increased incidence of PICU admissions for the pandemic influenza subtype A(H1N1)pdm09. We investigated
incidence and clinical characteristics of influenza in children admitted to PICUs during the first three post-pandemic
influenza seasons, using active screening.
Methods: We conducted a prospective surveillance study in 24 PICUs in Bavaria (Germany) from October 2010 to
September 2013. Influenza cases among children between 1 month and 16 years of age admitted to these PICUs
with acute respiratory infection were confirmed by PCR analysis of respiratory secretions.
Results: A total of 24/7/20 influenza-associated PICU admissions were recorded in the post-pandemic seasons
1/2/3; incidence estimates per 100,000 children were 1.72/0.76/1.80, respectively. Of all 51 patients, 80 % had
influenza A, including 65 % with A(H1N1)pdm09. Influenza A(H1N1)pdm09 was almost absent in season 2
(incidence 0.11), but dominated PICU admissions in seasons 1 (incidence 1.35) and 3 (incidence 1.17). Clinical
data was available for 47 influenza patients; median age was 4.8 years (IQR 1.6–11.0). The most frequent
diagnoses were influenza-associated pneumonia (62 %), bronchitis/bronchiolitis (32 %), secondary bacterial
pneumonia (26 %), and ARDS (21 %). Thirty-six patients (77 %) had underlying medical conditions. Median
duration of PICU stay was 3 days (IQR 1–11). Forty-seven per cent of patients received mechanical ventilation,
and one patient (2 %) extracorporeal membrane oxygenation; 19 % were treated with oseltamivir. Five children
(11 %) had pulmonary sequelae. Five children (11 %) died; all had underlying chronic conditions and were
infected with A(H1N1)pdm09. In season 3, patients with A(H1N1)pdm09 were younger than in season 1 (p = 0.020),
were diagnosed more often with bronchitis/bronchiolitis (p = 0.004), and were admitted to a PICU later after the
onset of influenza symptoms (p = 0.041).
(Continued on next page)
* Correspondence: Streng_A@ukw.de
1Department of Paediatrics, University of Würzburg, Josef-Schneider-Str. 2,
97080 Würzburg, Germany
Full list of author information is available at the end of the article
© 2015 Streng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Streng et al. BMC Infectious Diseases  (2015) 15:573 
DOI 10.1186/s12879-015-1293-1
(Continued from previous page)
Conclusions: Active screening showed a continued high incidence of A(H1N1)pdm09-associated PICU admissions
in the post-pandemic seasons 1 and 3, and indicated possible underestimation of incidence in previous German
studies. The age shift of severe A(H1N1)pdm09 towards younger children may be explained by increasing immunity
in the older paediatric population. The high proportion of patients with underlying chronic conditions indicates the
importance of consistent implementation of the current influenza vaccination recommendations for risk groups in
Germany.
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Background
Influenza is one of the most common vaccine-preventable
viral diseases, with the highest morbidity reported for
children and elderly patients [1, 2]. Influenza infections
during childhood usually present as mild respiratory
upper airway disease, but severe complications and fatal-
ities also occur, especially in children less than 2 years of
age and in children with underlying chronic conditions
[2–7]. However, 40–50 % of influenza-associated fatalities
occur in previously healthy children [4, 8].
Before the influenza A(H1N1)pdm09 pandemic in 2009/
2010, comparisons of clinical characteristics between
patients infected with different influenza types (A vs.
B) and between patients infected with different influ-
enza A subtypes showed only small differences when
controlling for age [9, 10]. During the pandemic, however,
some studies observed increased morbidity and mortality
among children compared to previous seasonal influenza
[6, 11–13], while other studies described the clinical fea-
tures of A(H1N1)pdm09 as being similar or even milder
[14, 15]. Acute respiratory distress syndrome (ARDS) and
fatal viral pneumonia was observed more frequently
during the pandemic [16]. Post-pandemic surveillance was
recommended, as circulation of A(H1N1)pdm09 was
expected to continue for several years, gradually assuming
a seasonal influenza pattern [16].
In Germany, influenza sentinel surveillance on outpa-
tients of all ages [17] confirmed that the first post-
pandemic season 2010/11 was dominated by influenza
A(H1N1)pdm09 (62 %), co-circulating with influenza B
(37 %) whereas A(H3N2) was rare (<1 %). During the
second season 2011/12, A(H1N1)pdm09 was rare (1 %),
whereas A(H3N2) was diagnosed in 75 % of cases and
co-circulated with influenza B (24 %). In the third season
2012/13, all three types/subtypes co-circulated in similar
proportions (34 % A(H1N1)pdm2009, 31 % A(H3N2),
and 35 % B).
Information on the incidence and clinical characteris-
tics of severe paediatric influenza resulting in intensive
care treatment and/or fatal outcome is still limited in
Germany, and post-pandemic data is thus far available
only for the season 2010/11 [18–20]. Based on cases
recorded by a nation-wide paediatric intensive care unit
(PICU) reporting system, the pre-pandemic (2005/06–
2007/08), pandemic (2009/10) and post-pandemic (2010/
11) annual incidence of severe influenza cases per 100,000
children below 15 or 17 years of age was estimated as
0.05, 0.8–1.0, and 0.4, respectively [18–20]. The data so
far available indicated a shift towards younger children in
A(H1N1)pdm09 cases from the pandemic to the first
post-pandemic season [20]. In these studies, it remained
unclear whether the higher pandemic and post-pandemic
incidence in children was caused by higher influenza
activity, heightened physician awareness, more frequent or
more sensitive influenza testing, or a more severe course
of disease of A(H1N1)pdm09 [18]. Furthermore, all
these previous studies may have been affected by under-
reporting, as influenza cases were reported at the discre-
tion of the PICU physician without systematic screening
for influenza in patients with severe acute respiratory
infection.
In the study presented here, we used active screening to
estimate the incidence of laboratory-confirmed influenza-
associated PICU admissions in one of Germany’s largest
federal states during the first three post-pandemic seasons.
Furthermore, we described the clinical characteristics of
influenza PICU patients and compared patients with se-
vere A(H1N1)pdm09 disease between the post-pandemic
seasons.
Methods
Study population and setting
Prospective, active surveillance was conducted in PICUs
of paediatric hospitals in Bavaria, Germany. On December
31st, 2010 roughly 2,001,700 children <17 years of age
were registered in Bavaria [21], representing 16 % of the
German population in this age group [22]. The annual
study population was defined as the sub-group of all chil-
dren in Bavaria at least 1 month and <17 years of age.
All 30 paediatric hospitals in Bavaria equipped for
paediatric intensive care treatment of children older than
1 month of age were invited to participate. These PICUs
reported a total of 432 intensive care beds (median 14,
IQR 11–16), including 207 beds (median 9, IQR 6–12)
equipped with ventilation facilities.
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Case definition and surveillance system
From October 2010 to September 2013 (season 1: Oct
2010–Sep 2011, season 2: Oct 2011–Sep 2012, season 3:
Oct 2012–Sep 2013), all patients who fulfilled the follow-
ing inclusion criteria were enrolled: i) admission to a par-
ticipating PICU with suspected acute respiratory infection
(ARI) of the upper or lower respiratory tract, with ARI-
related symptoms (for example, coryza, cough, or sore
throat); ii) age at PICU admission due to ARI at least
1 month and below 17 years of age; iii) parental written
informed consent. Enrolled children with PCR-confirmed
influenza were classed as influenza-associated ARI.
The PICU physician documented demographic charac-
teristics, underlying chronic medical conditions, influenza
vaccination status, diagnostic findings, ARI-associated diag-
noses and complications, treatment, duration of hospital
and PICU stay, and outcome in a structured question-
naire. A respiratory sample, usually a flocked nasopha-
ryngeal or pharyngeal swab, was collected on the day
of PICU admission for PCR-confirmation of influenza.
Microbiological testing for bacteria or fungi was at the
discretion of the PICU physician; pathogens detected
at usually sterile sites or in tracheal aspirates were classi-
fied as bacterial or fungal co-infection.
PCR confirmation of influenza
PCR confirmation of influenza was performed either at
the local laboratories of the participating PICUs using
influenza-specific PCR, or (in the majority of cases) at
the central laboratory at the Institute of Virology and
Immunobiology of the University of Würzburg using
multiplex PCR for respiratory viruses. For the latter,
respiratory samples were placed in a viral transport
medium (Mast Diagnostica GmbH, Reinfeld, Germany).
At the central laboratory, they were tested using the com-
mercial multiplex PCR ‘FTD® Respiratory pathogens 21’
(Fast Track Diagnostics, Luxembourg) to screen for re-
spiratory viruses (sensitivity and specificity of 99–100 %
compared to singleplex PCR assays for all included viruses
in clinical samples). Pathogens detected by the test kit
included influenza A and B viruses, respiratory syncytial
virus (RSV), parainfluenza virus (PIV) 1–4, coronavirus
(CoV) NL63, OC43, HKU1, and 229E, human metapneu-
movirus (hMPV), human bocavirus (hBoV), adenovirus
(AdV), rhinovirus (RhV), enterovirus (EV), parechovirus
(PV), and additionally Mykoplasma pneumoniae. Samples
positive for influenza A and B virus RNA in the multiplex
PCR were further analysed to determine the subtype
and lineage, respectively. Primers and probes specific
for influenza A(H1N1)pdm09 were included in the
‘FTD Respiratory pathogens 21’ kit. All samples positive
for influenza A virus RNA but negative for influenza A
virus (H1N1)pdm09 RNA were tested by a PCR specific
for influenza A virus H3.
Statistical analysis
All data was entered into a Microsoft Access database
and transferred to IBM SPSS 21.0 for statistical analysis.
Data was analysed descriptively (percentages, or median
with inter-quartile range, IQR). Comparisons between
groups were assessed for significance (p < 0.05, two-
sided) using Pearson’s Chi2-test or Fisher’s Exact test for
categorical data, and the Mann–Whitney U-test for
continuous data.
The minimum incidence of influenza-associated PICU
admissions per 100,000 children <17 years of age was
calculated for each season based on the observed num-
ber of influenza PICU patients with a residential address
in Bavaria. To correct for non-participating PICUs, the
estimates of the total number of PICU influenza cases
treated in all eligible PICUs in Bavaria per season were
derived taking into account the annual percentage of
participating PICUs. The annual study population was
used as denominator.
A similar questionnaire and case definition had been
used in previous studies on influenza-related PICU admis-
sion [18, 19]. Key variables were extracted from these pub-
lications for comparison purposes. Data from Streng et al.
[18] and the present study were pooled for statistical com-
parison of pre- and post-pandemic seasons.
Ethical considerations
The study was approved by the Ethical Committee of
the Medical Faculty, University of Würzburg, Germany.
Results
Participating PICUs and recruitment of ARI patients
During the 3-year-observation period, a total of 24 PICUs
participated in the study (80 % of the 30 eligible
PICUs in Bavaria), with 20/14/17 PICUs participating
in seasons 1/2/3 (67 %/47 %/57 % of all eligible PICUs).
Twelve of the 24 hospitals participated in all three seasons.
Reasons stated for non-participation in all or single sea-
sons were time limitations or staff shortages at the PICUs.
Participating and non-participating PICUs did not differ
significantly in the number of intensive care beds. The 24
participating PICUs enrolled a total of 572 (233/151/188)
ARI patients (median 13, IQR 5–30).
Frequency of PICU patients with PCR-confirmed influenza,
by type and subtype
Among the 572 enrolled PICU ARI patients, a total of
51 PCR-confirmed influenza patients (24/7/20 in seasons
1/2/3) were reported (Table 1). Influenza cases occurred
between December 2010 and March 2011, between
February and March 2012, and between December 2012
and April 2013, with 90.2 % of all influenza patients
admitted during the months January to March.
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Of the 51 influenza patients, 41 (80.4 %) were confirmed
by multiplex PCR, and 10 (19.6 %) by local PCR. Forty-
one patients (80.4 %) were diagnosed with influenza A,
and 10 (19.6 %) with influenza B (Table 1). Influenza A
was subtyped as A(H1N1)pdm09 in 33 and as A(H3N2) in
four patients; for four further patients, the A subtype was
not available or indeterminate. The frequency of influenza
types/subtypes differed strongly between observation years
(Table 1). Type A was diagnosed in 96 %/29 %/80 % of
PICU patients with PCR-confirmed influenza in seasons
1/2/3, respectively, including 79 %/14 %/65 % patients
with A(H1N1)pdm09. Influenza B was the dominating
type in season 2 (71.4 %).
Incidence estimates for influenza-associated PICU
admittance
Based on the observed cases, the minimum incidence
for PCR-confirmed influenza-associated PICU admission
per 100,000 children <17 years of age in Bavaria was cal-
culated as 1.15/0.36/1.03 for seasons 1/2/3, respectively.
Taking into account that the observed cases were based
on data from 67 %/47 %/57 % of all eligible PICUs, the
total number of influenza-associated PICU admissions in
Bavaria was estimated and corrected incidences were cal-
culated as 1.72/0.76/1.80 per 100,000 children <17 years.
Subtype-specific corrected incidences were 1.35/0.11/1.17
for A(H1N1)pdm09, 0.0/0.11/0.27 for A(H3N2), and 0.07/
0.54/0.36 for B.
Clinical characteristics of influenza-associated PICU
admissions
Demographic characteristics, hospital admittance and
length of stay
For 47 (92.2 %) of the 51 PCR-confirmed influenza PICU
patients, questionnaires with clinical data were available
(23/6/18 in seasons 1/2/3, respectively). Eighty-five per
cent of these were diagnosed with influenza A, including
68 % with A(H1N1)pdm09, and 15 % with influenza B.
Sixty per cent were male; median age was 4.8 years, with
51.1 % of children <5 years and 23.4 % <1 year of age
(Table 2).
After onset of ARI symptoms, children were admitted
to hospital after a median interval of 3.0 days; 83 % were
transferred to the PICU on the day of hospital admission
or the following day (Table 2). Two long-term hospital-
ized children (4.2 %) required PICU treatment due to
ARI and were diagnosed with suspected nosocomial influ-
enza A(H1N1)pdm09 infection. Median length of PICU
stay was 3.0 days and median length of total hospital stay
was 7.5 days (Table 2).
Underlying chronic conditions
Underlying chronic medical conditions were reported
for a total of 36 influenza PICU patients (76.6 %)
(Table 3). Chronic neurological diseases were most fre-
quent (34.0 %), followed by chronic lung disease (25.5 %),
preterm birth (21.3 %), cardiac malformations (17.0 %),
obesity (10.6 %), genetic disorders (8.5 %), and immuno-
compromising conditions (8.5 %).
Influenza vaccination status
Of 36 influenza PICU patients with underlying chronic
conditions, four (11.1 %) were too young (<6 months of
age) to have been immunized against influenza, and for two
patients (5.6 %), data on their influenza vaccination status
was unavailable. Twenty-nine (80.6 %) patients from this
risk group had not been vaccinated against influenza al-
though they would have been eligible. One immunocom-
promised child (2.8 %) had been vaccinated in October
2012, but was diagnosed with A(H3N2) in January 2013.
Clinical diagnoses
One or more specific influenza-associated diagnoses/com-
plications were reported for 42 (89.4 %) of the 47 children
(Table 4). The most frequent diagnosis was influenza-
associated pneumonia (61.7 %), followed by bronchitis/
bronchiolitis (31.9 %), and secondary bacterial pneumonia
(25.5 %). ARDS was reported for 10 (21.3 %) and sepsis
for six children (12.8 %); other complications were rare.
Table 1 Frequency of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus type/subtype (n = 51)
Influenza type/subtype
Seasons All patients A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) Ba
N (%) N (%) N (%) N (%) N (%) N (%)
Season 1 (Oct 2010–Sep 2011) 24 (100.0) 23 (95.8) 19 (79.2) 0 (0.0) 4 (16.7)b 1 (4.2)
Season 2 (Oct 2011–Sep 2012) 7 (100.0) 2 (28.6) 1 (14.3) 1 (14.3) 0 (0.0) 5 (71.4)
Season 3 (Oct 2012–Sep 2013) 20 (100.0) 16 (80.0) 13 (65.0) 3 (15.0) 0 (0.0) 4 (20.0)
Season 1–3 (Oct 2010–Sep 2013) 51 (100.0) 41 (80.4) 33 (64.7) 4 (7.8) 4 (7.8) 10 (19.6)
aInfluenza B lineages in Season 1/2/3: B-Victoria 0/3/0, B-Yamagata 0/1/1, B without lineage 1/1/3
bOne patient was diagnosed with both seasonal influenza A (without subtype) and A(H1N1)pdm09 by local PCR, and allocated for further analysis to the group
influenza A (subtype n.a.)
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Thirty-nine of the 47 patients (83.0 %) underwent a chest
radiograph.
Co-infections
In addition to influenza, laboratory-confirmed co-infections
were reported for 16 children (34.0 % out of 47). Of
these, seven (14.9 %) had viral, five (10.6 %) bacterial,
one (2.1 %) viral/bacterial, two (4.3 %) viral/fungal,
and one (2.1 %) bacterial/fungal co-infections. The most
frequent co-infecting virus was RSV (seven children).
Microbiological testing was documented for 33 patients
(70.2 %), with pathogens detected in usually sterile
Table 3 Underlying chronic medical conditions of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown
by virus type/subtype (n = 47)a
Influenza type/subtype Comparison of seasons
A(H1N1)pdm09c
Underlying medical conditions All patients A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) B S1 vs S3
N = 47 N = 40 N = 32 N = 4 N = 4 N = 7 p-value*
At least one medical condition; n (%) 36 (76.6) 32 (80.0) 24 (75.0) 4 (100.0) 4 (100.0) 4 (57.1) 0.667
Selected conditions
- Neurological disease; n (%) 16 (34.0) 14 (35.0) 13 (40.6) 1 (25.0) 0 (0.0) 2 (28.6) 1.000
- Chronic lung diseaseb; n (%) 12 (25.5) 12 (30.0) 11 (34.4) 0 (0.0) 1 (25.0) 0 (0.0) 1.000
- Pre-term birth; n (%) 10 (21.3) 9 (22.5) 8 (25.0) 1 (25.0) 0 (0.0) 1 (14.3) 0.210
- Cardiac malformation; n (%) 8 (17.0) 8 (20.0) 3 (9.4) 3 (75.0) 2 (50.0) 0 (0.0) 0.558
- Obesity; n (%) 5 (10.6) 5 (12.5) 3 (9.4) 0 (0.0) 2 (50.0) 0 (0.0) 0.245
- Genetic disorder; n (%) 4 (8.5) 3 (7.5) 3 (9.4) 0 (0.0) 0 (0.0) 1 (14.3) 0.558
- Immunocompromised; n (%) 4 (8.5) 2 (5.0) 0 (0.0) 1 (25.0) 1 (25.0) 2 (28.6) n.a.
- Renal disease; n (%) 1 (2.1) 1 (2.5) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0.419
- Other underlying conditions; n (%) 9 (19.1) 8 (20.0) 5 (15.6) 2 (50.0) 1 (25.0) 1 (14.3) 0.134
n.a. not available, vs versus
*Fisher’s Exact test or Mann–Whitney U-test, respectively
aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
bIncluding asthma, broncho-pulmonary dysplasia, other chronic lung disease
cComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)
Table 2 Demographic characteristics and details on PICU/hospital admission of PCR-confirmed influenza patients in Bavarian PICUs,
2010–2013. Data are shown by virus type/subtype (n = 47)a
Influenza type/subtype Comparison of
seasons
A(H1N1)pdm09c
Characteristics All patients A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) B S1 vs S3
N = 47 N = 40 N = 32 N = 4 N = 4 N = 7 p-value*
Male sex; n (%) 28 (59.6) 24 (60.0) 18 (56.3) 3 (75.0) 3 (75.0) 4 (57.1) 0.481
Age at ICU admission, in years
(median, IQR)
4.8 (1.6–11.0) 4.7 (1.1–11.1) 5.4 (1.6–11.3) 0.9 (0.6–4.4) 4.9 (2.3–10.4) 5.0 (2.3–9.4) 0.020
Interval between onset of ARI
symptoms and ICU admission,
in days (median, IQR)b
3.0 (2.0–5.3) 3.0 (1.0–6.0) 3.5 (1.0–5.8) 2.5 (2.0–10.5) 3.0 (n.a.) 3.0 (1.5–5.0) 0.041
Interval between onset of ARI
symptoms and hospital admission,
in days (median, IQR)b
3.0 (1.0–5.0) 3.0 (1.0–5.0) 3.0 (1.0–5.0) 2.5 (2.0–4.5) 2.0 (n.a.) 3.0 (1.5–4.0) 0.217
Duration of ICU stay, in days
(median, IQR)
3.0 (1.0–11.0) 3.5 (2.0–12.5) 3.0 (1.3–12.3) 9.5 (7.3–29.0) 6.5 (2.0–16.3) 1.0 (1.0–11.0) 0.837
Duration of hospital stay, in days
(median, IQR)
7.5 (4.0–16.3) 8.0 (4.0–16.0) 7.0 (4.0–16.0) 11.0 (8.8–59.0) 13.0 (7.3–20.3) 5.0 (3.0–22.0) 0.953
n.a. not available, vs versus
*Fisher’s Exact Test or Mann–Whitney U-test, respectively
aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
bDate of ARI symptom onset missing for nine patients
cComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)
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material from two patients (Escherichia coli (1), Can-
dida sp. (1)) and from tracheal aspirates of seven intu-
bated patients (Candida sp. (2), Pseudomonas aeruginosa
(2), Streptococcus sp. (2), Enterococcus faecium (1), Escher-
ichia coli (1) and Moraxella catarrhalis (1)).
Patient treatment and outcome
The majority of the 47 PICU patients were treated intra-
venously with antibiotics (72.3 %), and with antipyretics
(70.2 %) (Table 5). Thirteen children (27.7 %) received
antiviral treatment, including nine (19.1 %) patients
Table 4 Diagnoses/complications of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus
type/subtype (n = 47)a
Influenza type/subtype Comparison of seasons
A(H1N1)pdm09b
Complications All patients A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) B S1 vs S3
N = 47 N = 40 N = 32 N = 4 N = 4 N = 7 p-value*
At least 1 specific complication; n (%) 42 (89.4) 36 (90.0) 29 (90.6) 3 (75.0) 4 (100.0) 6 (85.7) 0.497
Influenza-associated pneumonia; n (%) 29 (61.7) 26 (65.0) 22 (68.8) 1 (25.0) 3 (75.0) 3 (42.9) 1.000
Bronchitis/bronchiolitis; n (%) 15 (31.9) 13 (32.5) 8 (25.0) 3 (75.0) 2 (50.0) 2 (28.6) 0.004
Secondary bacterial pneumonia; n (%) 12 (25.5) 10 (25.0) 10 (31.3) 0 (0.0) 0 (0.0) 2 (28.6) 0.452
ARDS; n (%) 10 (21.3) 9 (22.5) 7 (21.9) 2 (50.0) 0 (0.0) 1 (14.3) 0.099
Sepsis; n (%) 6 (12.8) 6 (15.0) 4 (12.5) 1 (25.0) 1 (25.0) 0 (0.0) 1.000
Febrile convulsions; n (%) 3 (6.4) 2 (5.0) 2 (6.3) 0 (0.0) 0 (0.0) 1 (14.3) 1.000
Encephalitis/encephalopathy; n (%) 1 (2.1) 1 (2.5) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Laryngitis/pseudocroup; n (%) 1 (2.1) 1 (2.5) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Otherc; n (%) 6 (12.8) 5 (12.5) 5 (15.6) 0 (0.0) 0 (0.0) 1 (14.3) 1.000
n.a. not available, vs versus
*Fisher’s Exact test
aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
bComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)
cOther complications, excluding the pre-defined complications otitis media, status asthmaticus, and myocarditis (for these pre-defined complications, no case
was reported)
Table 5 Treatment and outcome of PCR-confirmed influenza patients in Bavarian PICUs, 2010–2013. Data are shown by virus
type/subtype (n = 47)a
Influenza type/subtype Comparison of seasons
A(H1N1)pdm09c
Treatment All A A(H1N1)pdm09 A(H3N2) A (subtype n.a.) B S1 vs S3
N = 47 N = 40 N = 32 N = 4 N = 4 N = 7 p-value*
Antiviral drugsb; n (%) 13 (27.7) 12 (30.0) 9 (28.1) 1 (25.0) 2 (50.0) 1 (14.3) 1.000
Antibiotics i.v.; n (%) 34 (72.3) 31 (77.5) 25 (78.1) 2 (50.0) 4 (100.0) 3 (42.9) 0.676
Antipyretics; n (%) 33 (70.2) 28 (70.0) 22 (68.8) 2 (50.0) 4 (100.0) 5 (71.4) 0.452
Catecholamines; n (%) 13 (27.7) 13 (32.5) 11 (34.4) 1 (25.0) 1 (25.0) 0 (0.0) 1.000
Inhalation therapy; n (%) 13 (27.7) 13 (32.5) 11 (34.4) 2 (50.0) 0 (0.0) 0 (0.0) 1.000
Oxygen; n (%) 31 (66.0) 28 (70.0) 20 (62.5) 4 (100.0) 4 (100.0.) 3 (42.9) 0.275
Intratracheal ventilation; n (%) 15 (31.9) 14 (35.0) 12 (37.5) 1 (25.0) 1 (25.0) 1 (14.3) 1.000
CPAP; n (%) 11 (23.4) 9 (22.5) 7 (21.9) 0 (0.0) 2 (50.0) 2 (28.6) 0.084
Other; n (%) 14 (29.8) 13 (32.5) 10 (31.3) 2 (50.0) 1 (25.0) 1 (14.3) 0.247
Outcome
Sequelae; n (%) 5 (10.6) 4 (10.0) 3 (9.4) 1 (25.0) 0 (0.0) 1 (14.3) 0.548
Death; n (%) 5 (10.6) 5 (12.5) 5 (15.6) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
n.a. not available, vs versus, i.v. intravenous
*Fisher’s Exact test or Mann–Whitney U-test, respectively
aClinical data was not available for one influenza A(H1N1)pdm09 and three influenza B patients
bOseltamivir (n = 8), oseltamivir plus acyclovir (n = 1), acyclovir (n = 3), gancyclovir plus valgancyclovir (n = 1)
cComparison restricted to influenza A(H1N1)pdm09 patients from Season 1 (S1; Oct10–Sep 11; n = 18) and Season 3 (S3; Oct12–Sep 13; n = 13)
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treated with oseltamivir (four patients received acyclovir,
and one patient ganciclovir and valgancyclovir due to
other reasons). The median delay between onset of ARI
symptoms and oseltamivir treatment was 3.5 days (range
0 to 10 days), with three children receiving treatment
within 2 days after symptom onset. Oseltamivir treat-
ment was associated with the presence of a viral or other
co-infection (p = 0.045), and with a longer stay at the
PICU (median 11 days, IQR 2.5–27.5; p = 0.043). Thirteen
(27.7 %) children each were treated with catecholamines
and with inhalation therapy, mainly with bronchodilators.
A total of 22 children (46.8 %) required mechanical venti-
lation; of these, 11 (23.4 %) received only intratracheal
ventilation, seven (14.9 %) only CPAP, and four (8.5 %)
both. One child (2.1 %) with an immunosuppressed condi-
tion, infected with influenza A(H3N2), RSV, Epstein-Barr
virus and Candida sp., was treated with extracorporeal
membrane oxygenation (ECMO).
Fatalities and sequelae
Five children (10.6 %), infected with A(H1N1)pdm09,
died at an age of 4 to 11 years; four were male patients
(Table 6). Four of these children suffered both from
severe neurological conditions (two children with pre-
vious peripartal asphyxia and spastic tetraparesis; one
child with cerebral paresis and tetraspasticity; one child
with congenital cerebral disorder), and from chronic
pulmonary conditions; two of these four children were
also born pre-term. Influenza-associated pneumonia was
diagnosed in all four of these children; three additionally
had secondary bacterial pneumonia, and one child also
developed sepsis. For the fifth child, obesity was reported
as the only risk factor; and sepsis and suspected encephal-
itis as complications. Bacterial co-pathogens were detected
in three of these five children and suspected in one child;
two viral and two fungal co-infections were also reported.
All five children received intratracheal ventilation, antibi-
otics and catecholamines; two were additionally treated
with antiviral medication. Death occurred 1, 2, 4, 19, and
26 days after PICU admission, with ARDS reported as
cause of death in three children.
Sequelae were reported for five patients (10.6 %): state
after surgery due to pleural effusion/empyema in two
children; increased oxygen requirements in two children
who had previously already received oxygen therapy at
home; damage of the lung after high-pressure ventilation
in one child.
Comparison of PICU patients infected with influenza
A(H1N1)pdm09 in the first and the third post-pandemic
season
Influenza A(H1N1)pdm09 from season 1 (n = 18) were
compared to patients from season 3 (n = 13) (Tables 2,
3, 4, 5). Patients with influenza A(H1N1)pdm09 were
significantly older in season 1 (median 7.1, IQR 3.3.–12.5)
than in season 3 (median 1.7; IQR 0.1–8.3; Table 2).
Figure 1 shows the difference in age distribution between
both seasons, and the high proportion of children below
2 years of age as opposed to low proportions in all other
age groups in season 3. After onset of symptoms, children
were admitted to a PICU after a significantly shorter
period, with a median of 3 days (IQR 1–4) in season 1
compared to 6 days (IQR 2.0–7.5) in season 3 (Table 2).
In season 1, significantly fewer children were diagnosed
with bronchitis/bronchiolitis (Table 4), and they tended to
require CPAP treatment less frequently than in season 3
(11.1 % vs. 41.7 %, p = 0.084, Table 5).
Comparison of PICU patients infected with influenza in
pre-pandemic and post-pandemic seasons
In the pre-pandemic period, median duration of PICU
stay was longer (19 days), and children were more often
diagnosed with encephalitis/encephalopathy (25 %) and
co-infections (65 %) than in later periods (Table 7). The
proportion of children with influenza-associated pneu-
monia was highest (74 %) during the pandemic, whereas
secondary bacterial pneumonia (17 %), bronchitis/
bronchiolitis (12 %) and sepsis (6 %) were reported
less frequently during the pandemic than in the pre- and
post-pandemic seasons. Oseltamivir treatment decreased
significantly in the post-pandemic period (Table 7).
Discussion
During the first three post-pandemic seasons 2010/11,
2011/12 and 2012/13, active screening of children with
acute respiratory infection admitted to 24 paediatric
intensive care units in Bavaria identified a total of 51
PCR-confirmed influenza cases, resulting in annual inci-
dence estimates of 1.7, 0.7, and 1.8 influenza-associated
PICU admissions per 100,000 children, respectively. These
figures would, by extrapolation, correspond to a total
number of 559 children with influenza-associated PICU
admission in Germany within the 3-year post-pandemic
period, with an annual average of 186 children. This
is almost 28 times as high as the annual average of
six to seven influenza-associated PICU admissions de-
tected by nation-wide PICU surveillance in Germany
during three pre-pandemic years without active screening
[18]. Furthermore, the incidence estimates for the subtype
A(H1N1)pdm09 derived from our active screening study
were higher in the first and third post-pandemic seasons
(1.35 and 1.17, respectively) than previous incidence
estimates for PICU patients in the pandemic (0.8–1.0)
and the first post-pandemic (approximately 0.4) sea-
son in Germany [19, 20]. Thus, our results indicate
possible underreporting in previous studies, and show
a continued high level of A(H1N1)pdm09-associated
PICU admissions even 3 years after the pandemic.
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Table 6 Fatalities in five out of 47 patients with PCR-confirmed influenza in Bavarian PICUs, 2010–2013
Patient PICU admittance
(season)
Age
(years)
Influenza type/
subtype
Co-pathogen(s)
detecteda
Underlying chronic
condition
Influenza
vaccination
Complications Antiviral treatment
(days)
Antibiotics
i.v. (days)
Cause of death
1 2010/11 10 A(H1N1)pdm09 Escherichia coli Obesity No ARDS, sepsis, convulsion (encephalitis
suspected)
Acyclovir (2) Yes (2) ARDS, Sepsis
2 2010/11 4 A(H1N1)pdm09 Streptococcus sp.,
Candida sp.
Neurologic No Pneumonia, secondary bacterial
pneumonia, pleural effusion
No Yes (10) Circulatory
insufficiency
Pulmonal
Pre-term birth
3 2010/11 4 A(H1N1)pdm09 RSV Pseudomomas
aeruginosa
Neurologic No Pneumonia, secondary bacterial
pneumonia, ARDS
No Yes (19) ARDS
Pulmonal
Pre-term birth
Obesity
4 2012/13 11 A(H1N1)pdm09 RSV, Candida sp. Neurologic No Pneumonia, secondary bacterial
pneumonia, bronchitis, ARDS, sepsis
Oseltamivir (5) Yes (22) ARDS, circulatory
insufficiency
Pulmonal
5 2012/13 11 A(H1N1)pdm09 None Neurologic No Pneumonia No Yes (4) Respiratory
failure
Pulmonal
aViral co-infections were detected either by local PCR or central multiplex PCR; bacteria and fungi were identified from blood culture or tracheal aspirates (intratracheal ventilation)
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In our study, the proportions of children with bacteria-
associated complications (secondary bacterial pneumonia,
sepsis) were similar to the proportions observed during
the pre-pandemic period, but appeared higher than those
observed during the pandemic 2009/10 [19]. The lower
proportions observed during the pandemic might be
explained by the time shift of the peak of influenza
cases, which was observed as early as November 2009
in Germany [19]. Thus, the pandemic influenza peak
did not coincide with the seasonal peak of Streptococcus
pneumoniae, the bacterial pathogen most frequently asso-
ciated with community-acquired influenza [23].
Antiviral treatment patterns changed considerably dur-
ing the post-pandemic period, with a decrease in the
proportion of paediatric influenza cases receiving oselta-
mivir from previously 50 % [18] and 61 % [19] to 19 %.
Oseltamivir is considered to be most advantageous when
administered within the first 48 h of influenza disease.
The reduced use in the post-pandemic period may there-
fore be partly due to the fact that median time between
onset of influenza symptoms and PICU admission was
longer than during the pandemic (3 vs. 2 days [19]).
Increasing uncertainty regarding the effectiveness of osel-
tamivir in the treatment of paediatric influenza may also
have played a role [24, 25]. Post-pandemic oseltamivir
treatment was associated with co-infections and longer
PICU stay, suggesting that it were mainly children with
severe complications or with serious underlying condi-
tions who received this medication.
In our study, about two-thirds of influenza cases and all
fatalities were A(H1N1)pdm09-associated. During the post-
pandemic seasons 1/2/3, the proportion of A(H1N1)pdm09
cases among the PICU patients was 79 %/14 %/65 %
and, thus, considerably higher than the proportion of
this subtype reported among outpatients by national
influenza surveillance (65 %/1 %/34 %) [17]. This ob-
servation suggests that A(H1N1)pdm09 may be asso-
ciated more often with a severe course of influenza
requiring PICU treatment than other influenza types/
subtypes. Similar observations on the proportion of
A(H1N1)pdm09-associated PICU admissions have been
reported in the United States [9].
Comparison of PICU patients with A(H1N1)pdm09
between the post-pandemic seasons showed that median
age was 1.7 years in the third season and, thus, signifi-
cantly lower than in the first season. A significant age
shift towards younger children, from a median age of 5
to 3 years, had already been observed in a comparison of
the pandemic and the first post-pandemic season in
Germany [20]. The continued shift towards younger
patients in the third season is likely to be due to in-
creasing immunity in the older paediatric population,
after previous contact with A(H1N1)pdm09. Seropreva-
lence data from Germany had already shown evidence for
A(H1N1)pdm09 infection in as many as 25 % of children
aged 1–4 years and 48 % of 5–17 year-old children for the
pandemic season 2009/10 [26]. A similar shift towards
younger hospitalized children [27, 28] and towards youn-
ger children with severe paediatric A(H1N1)pdm09-asso-
ciated influenza from the pandemic season to the first
post-pandemic season had also been detected in other
European countries [28–31].
In Germany, paediatric influenza vaccination for pan-
demic influenza A(H1N1)pdm09 was recommended and
funded for all children as monovalent vaccination from
October 2009 to July 2010 [32]. For seasonal influenza,
however, paediatric influenza vaccination was and is
currently recommended only for specific risk groups
with underlying chronic conditions [33]. Vaccination
uptake was low, even in this target group. Pre-pandemic
vaccination rates were 5 % for all children and about
15 % for children with chronic underlying conditions in
2007/2008 [34]. For the pandemic and post-pandemic
seasons, no data on vaccination rates is available for
children, but vaccination rates as low as 14 % (2009/10)
and 11 % (2010/11) were reported for adults, with a
vaccination rate of only 17 % even for risk group
adults [35]. In our study, more than 75 % of influenza-
associated PICU patients were children with underlying
chronic conditions. Analysis of their reported influenza
Fig. 1 Age distribution of children with PCR-confirmed influenza
A(H1N1)pdm09 infection treated in PICUs in Bavaria (figure
corresponding to [20]). Data are given in %, by age group and
season. Season 1: Oct10–Sep11 (n = 18), Season 3: Oct12–Sep13
(n = 13); Season 2: Oct11–Sep12 (n = 1) is not shown
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vaccination status showed that among these were a high
proportion of vaccine-eligible but unvaccinated children.
Patients with chronic conditions too young to be vacci-
nated and other paediatric risk groups, such as otherwise
healthy children below 2 years of age, are not covered by
the current German recommendation. All these groups
could profit considerably from universal influenza vaccin-
ation for children, either directly or by herd protection. In
contrast to the situation in Germany, in the United States
universal influenza vaccination for all children older than
6 months of age has been established, and vaccination
coverage reached a level of approximately 41 % in 2013
[36]. Compared to 348 influenza-associated paediatric
deaths observed in the United States during the pan-
demic 2009/10, only 79 were observed in the strong
A(H1N1)pdm09 season 2013/14 [37]. This might partly
be explained by increasing immunity in children after
previous A(H1N1)pdm09 infection, but may in part also
be a result of the influenza vaccination program [37]. In
England, a universal childhood vaccination programme
with a new live attenuated influenza vaccine (LAIV) with
intra-nasal application was started in the 2013/14 influ-
enza season [38]. First results showed an overall uptake of
53 % in primary school aged children, indicating a good
acceptance of LAIV, and suggesting direct and indirect
impacts on disease incidence, including reduction of paedi-
atric influenza-associated hospitalisations.
To our knowledge, our study is the first in Europe to
investigate paediatric influenza in PICU patients during
the first three post-pandemic seasons after the 2009/10
pandemic. The strengths of our study include the multi-
centre design covering the majority of PICUs in Bavaria,
the active screening for influenza in patients admitted to
PICUs, and PCR-confirmation of all influenza cases. A
limitation is that the corrected incidence estimates were
based on the assumption that participating and non-
participating PICUs treated a similar number of severe
paediatric influenza patients. Although PICUs of both
groups were of similar size, some of the non-participating
PICUs, where paediatricians indicated lack of time as
reason for non-participation, may have treated a higher
number of patients, or patients with higher acuity. Further
limitations include potential over- and underreporting in
participating PICUs. On the one hand, due to different
hospitalization rules some children may have been admit-
ted to PICUs mainly for the purpose of monitoring their
course of influenza disease more closely, thus resulting in
an overestimate of severe cases. On the other hand, some
parents of children with severe influenza may have refused
study participation, or children with a fulminant course of
influenza disease may have died before they were admitted
to a PICU [4]. Thus, the high incidence estimates derived
in this study may still underestimate the true burden of
severe influenza.
Table 7 Summary of key variables from studies of PICU-associated influenza in Germany, 2005–2013. Data were collected in
Germany during the pre-pandemic period 2005/06–2007/08 [18], in Germany during the pandemic season 2009/10 [19], and in
Bavaria (Southern Germany) during the post-pandemic period 2010/11–2012/13 (this study)
Key variables of PICU patients Pre-pandemic
(2005/06–2007/08)
Pandemic
(2009/10)
Post-pandemic
(2010/11–2012/13)
Pre-pandemic vs.
post-pandemicb
N = 20 N = 89a N = 47 p-value
Male sex; n (%) 12 (60) 56 (60) 28 (60) 1.000
Age at ICU admission, in years (median, IQR) 7.5 (0.5–12.75) 4.5 (1.3–9.3) 4.8 (1.6–11.0) 0.727
Duration of ICU stay, in days (median, IQR) 19 (12–38) 8 (3–17) 3 (1–11) 0.006
Chronic underlying conditions; n (%) 11 (55) 63 (74) 36 (77) 0.089
Complications/diagnoses
Influenza-associated pneumonia; n (%) 12 (60) 66 (74) 29 (62) 1.000
Bronchitis/bronchiolitis; n (%) 6 (30) 11 (12) 15 (32) 1.000
Secondary bacterial pneumonia; n (%) 5 (25) 15 (17) 12 (26) 1.000
ARDS; n (%) 5 (25) 22 (25) 10 (21) 0.756
Sepsis; n (%) 3 (15) 5 (6) 6 (13) 1.000
Encephalitis/encephalopathy; n (%) 5 (25) 6 (7) 1 (2) 0.008
Co-infections; n (%) 13 (65) n.a. 16 (34) 0.030
Oseltamivir treatment; n (%) 10 (50) 51 (61) 9 (19) 0.017
Mechanical ventilation; n (%) 10 (50) 56 (65) 22 (47) 1.000
Death; n (%) 2 (10) 11 (12) 5 (11) 1.000
Influenza A(H1N1)pdm09; n (%) 0 (0) 89 (100) 32 (68) <0.001
a89 cases with PICU treatment; proportions may refer to slightly lower patient numbers, see Altmann et al. 2011 [19]
bKey data from this study were pooled with data from Streng et al. 2011 [18] and compared using Fisher’s Exact test or Mann–Whitney U-test, respectively
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Conclusions
The incidence estimates of influenza A(H1N1)pdm09-
associated PICU admissions, derived from active screen-
ing of PICU patients with acute respiratory infections,
reached similarly high levels in the first and third post-
pandemic seasons. Both incidence estimates were higher
than those previously reported by nation-wide PICU sur-
veillance for the pandemic and the first post-pandemic
season, suggesting possible underreporting in previous
studies without active screening. Comparison of the first
and third post-pandemic seasons indicated an age shift
of severe A(H1N1)pdm09 towards younger children,
which might be explained by increasing immunity in the
older paediatric population. The large proportion of
children with underlying chronic conditions indicates
the need for a more consistent implementation of the
current recommendations for influenza vaccination of
specific risk groups in Germany. These children could
also profit from herd protection, if universal influenza
vaccination was successfully introduced in Germany.
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